9166 Activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2, in adenocarcinoma of the lung with HER2neu kinase domain mutations

J.De Greve; E.Teugels; C.Geers; J.DeMey; P.in tveld; L.Decoster; M.Taton; M.Shahidi; D.Galdermans; D.Schallier

首页> 外文期刊>European Journal of Cancer Supplements >9166 Activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2, in adenocarcinoma of the lung with HER2neu kinase domain mutations

【24h】

9166 Activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2, in adenocarcinoma of the lung with HER2neu kinase domain mutations

机译：9166 BIBW 2992（一种不可逆的EGFR和HER2抑制剂）在具有HER2neu激酶结构域突变的肺腺癌中的活性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共2页
作者
J.De Greve; E.Teugels; C.Geers; J.DeMey; P.in tveld; L.Decoster; M.Taton; M.Shahidi; D.Galdermans; D.Schallier;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2eu [J] . DeGrèveJ., TeugelsE., GeersC., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2012,第1期

机译：阿法替尼（BIBW 2992）在HER2 / neu激酶结构域突变的肺腺癌患者中的临床活性
2. EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992 [J] . James F. Spicer, Sarah M. Rudman Targeted Oncology . 2010,第4期

机译：非小细胞肺癌（NSCLC）中的EGFR抑制剂：双重不可逆EGFR / HER2抑制剂的新兴作用BIBW 2992
3. EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. [J] . Spicer JF, Rudman SM Targeted oncology . 2010,第4期

机译：非小细胞肺癌（NSCLC）中的EGFR抑制剂：双重不可逆EGFR / HER2抑制剂BIBW 2992的新兴作用。
4. Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma [C] . Yeul Hong Kim, Hye Sook Kim, Jae Sook Sung, Molecular Medicine TRI-CON. . 2014

机译：下一代测序对非小细胞肺癌抗蛋白酶激酶抑制剂进行下一代测序检测的低负荷EGFR突变的预测疗效
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. A phase I dose escalation study of BIBW 2992 an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on 2-week off schedule in patients with advanced solid tumours [O] . F A L M Eskens, C H Mom, A S T Planting, 2008

机译：BIBW 2992的I期剂量递增研究是表皮生长因子受体1（EGFR）和2（HER2）酪氨酸激酶的不可逆双重抑制剂在进展期2周2周的时间表中用于晚期实体瘤患者
7. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. [O] . De Greve, J., Teugels, E., Geers, C., 2012

机译：阿法替尼（BIBW 2992）在具有HER2 / neu激酶结构域突变的肺腺癌患者中的临床活性。

9166 Activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2, in adenocarcinoma of the lung with HER2neu kinase domain mutations

著录项

相似文献

相关主题

期刊订阅